High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib

Who May Qualify: - Age 19 years or older - Idiopathic Pulmonary Fibrosis (IPF) diagnosis according to American Thoracic Society and/or European Respiratory Society consensus criteria - Appropriate candidate for pulmonary rehabilitation - prescribed nintedanib by their treating physician or currently on nintedanib - 6 minute walk distance 50m or more - Oxygen saturation 92% or more by pulse oximetry at rest while breathing room air - Clinically stable for the preceding 6 weeks Who Should NOT Join This Trial: - Contraindication to treatment with nintedanib (based on Canadian labeling) - Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease) - Other significant extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and/or oxygenation - Forced vital capacity (FVC) less than 50% or Diffusion capacity for carbon monoxide (DLCO) less than 25% - Concurrent or recent participation (less than 6 months) in a pulmonary rehabilitation program - Use of prednisone greater than 10 mg/day for more than 2 weeks within 3 months of the first study visit - Use of pirfenidone within 4 weeks of screening - Significant emphysema (less than 10% volume on high resolution computed tomography (HRCT) or forced expiratory volume at one second (FEV1)/FVC less than 0.70) Always talk to your doctor about whether this trial is right for you.